Literature DB >> 10117014

Willingness to pay for antihypertensive therapy--results of a Swedish pilot study.

M Johannesson1, B Jönsson, L Borgquist.   

Abstract

In this methodological study the results of a Swedish pilot study about willingness to pay for antihypertensive therapy are presented. The aim of the study was to test the feasibility of the contingent valuation (CV) method in this area. Open-ended and discrete CV questions were compared in a mail questionnaire. The open-ended CV question did not work well. The answers to the discrete question, analysed by logistic regression analysis, indicated a willingness to pay in the range SEK 2500-5000 per year for antihypertensive therapy. Further studies should be undertaken to explore the reliability and the validity of the CV method.

Mesh:

Year:  1991        PMID: 10117014     DOI: 10.1016/0167-6296(91)90025-i

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  17 in total

Review 1.  Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

Authors:  E McIntosh; C Donaldson; M Ryan
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

2.  Unexpected yes- and no-answering behaviour in the discrete choice approach to elicit willingness to pay: a methodological comparison with payment cards.

Authors:  Thomas Hammerschmidt; Hans-Peter Zeitler; Reiner Leidl
Journal:  Int J Health Care Finance Econ       Date:  2003-09

3.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

4.  Economic evaluation of drug therapy: a review of the contingent valuation method.

Authors:  M Johannesson; P O Johansson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

5.  Economic evaluation in healthcare. A brief history and future directions.

Authors:  K Blumenschein; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

6.  The impact of user charges on the consumption of drugs. Empirical evidence and economic implications.

Authors:  U G Gerdtham; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

7.  Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

Authors:  B J O'Brien; S Novosel; G Torrance; D Streiner
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 8.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  Estimating the economic benefits of avoiding food-borne risk: is 'willingness to pay' feasible?

Authors:  C Donaldson; T Mapp; M Ryan; K Curtin
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

10.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.